



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

VINILO

Low grade gliomas (LGG) are the most frequent brain tumour type in children. More than 50% of these tumours will progress within the first 5 years after treatment start and patients with progression need a second therapy. In most cases, patients are still young and the risk of side effects from radiotherapy will call for another medical treatment. The VINILO study wants to improve the cure of LGG patients that have not responded to the previous treatment, or patients with relapsed tumours. The Institut Gustave Roussy in France is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

Vinblastine (Velbe®) is an effective medicine for low grade gliomas. Tolerance of the treatment is good allowing prolonged therapy. Nilotinib is a medicine that has a potential to work against glioma tumour cells and it is well tolerated by children with brain tumours. In the phase I part of the study, tolerance of the combined treatment was tested to determine the optimal dose. In phase II of the study the combination of Vinblastine and Nilotinib was compared to the standard treatment of Vinblastine alone. The study does not recruit any more patients and is in its evaluation phase.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89